Caroline Robert

SRM Institute of Science and Technology — India

Medicine · Health Sciences

154h-index156.3kcitations1.5kworks10.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(523), Melanoma and MAPK Pathways(508), CAR-T cell therapy research(389), Cutaneous Melanoma Detection and Management(295), Immunotherapy and Immune Responses(242)

Publications1.5k total

Mutation du gène CNNM2 : une nouvelle cause génétique de chondrocalcinose
Revue du Rhumatisme·2025
Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
2025Open Access
Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 5 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
2025Open Access
Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Immunothérapie combinée par ipilimumab plus nivolumab dans le carcinome de Merkel métastatique réfractaire : efficacité spectaculaire sur une localisation intracardiaque
Annales de Dermatologie et de Vénéréologie - FMC·2025
Étude randomisée de phase 3 comparant le cémiplimab adjuvant à un placebo et analyse des tumeurs primaires secondaires (TPS) dans le carcinome épidermoïde cutané à haut risque (CEC) : l’essai C-POST
Annales de Dermatologie et de Vénéréologie - FMC·2025
600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma
Regular and Young Investigator Award Abstracts·2025Open Access
611 RP1 plus nivolumab in patients with and without prior BRAF-directed therapy: a subgroup analysis of patients with anti-PD-1-failed <i>BRAF</i> -mutant melanoma from the IGNYTE clinical trial
Regular and Young Investigator Award Abstracts·2025Open Access
International real-world study of combination immunotherapy sequences in metastatic melanoma
Journal for ImmunoTherapy of Cancer·2025Open Access
1327 Biomarker and updated clinical data for RP1 plus nivolumab in anti-PD-1-failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade
2025Open Access
P09.14.A OPTIMIZING MRI COIL SETUPS FOR ENHANCED DTI IN RADIOTHERAPY WITH IMMOBILIZATION DEVICES: TOWARDS CLINICAL INTEGRATION OF WHITE MATTER TRACTS
Neuro-Oncology·2025Open Access
Novel CNNM2 variant causing hypomagnesemia and early-onset calcium pyrophosphate deposition disease: A case report
Joint Bone Spine·2025Open Access
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Nature Medicine·2025· 3 citedOpen Access
Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy
2025Open Access
1684TiP Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: The phase II INTerpath-012 study
Annals of Oncology·2025
Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1
2025Open Access
page 1 of 74Next →

Frequent Co-authors

Dirk Schadendorf(18), Antoni Ribas(18), James Larkin(16), Jedd D. Wolchok(15), Georgina V. Long(15), Omid Hamid(15), F. Stephen Hodi(14), Célèste Lebbé(12), Jeffrey S. Weber(12), Jean‐Jacques Grob(12), Axel Hauschild(11), Reinhard Dummer(11), Keith T. Flaherty(11), Vanna Chiarion‐Sileni(11), John B.A.G. Haanen(10), Claus Garbe(10), Alexander M.M. Eggermont(10), Ana Arance(10), Adil Daud(10), Paolo A. Ascierto(9)